Panelists discuss how disease-modifying therapies for immunoglobulin A (IgA) nephropathy, though initially more expensive ...

Panelists discuss how early diagnosis of immunoglobulin A (IgA) nephropathy enables timely interventions that can ...

Travere Therapeutics stock did suffer a bit of setback last week as the FDA moved back the anticipated decision date on a ...

Early findings from the SPARTAN phase II trial, presented at the National Kidney Foundation (NKF) Spring Clinical Meeting, ...

Over a 35-year journey with a rare kidney disease, Ginger Murphy has become an advocate for her own health and welcomes the ...

Vera Therapeutics faces a pivotal moment with Phase 3 data expected soon. Depending on the result, the stock may spike or ...

IgA nephropathy is a progressive, autoimmune, chronic disease that predominantly affects adults between the ages of 20 and 40, with an annual global incidence of 2.5 cases per 100,000 people. Despite ...